Literature DB >> 17684125

Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.

Sarah E Daugherty1, Elizabeth A Platz, Yin Yao Shugart, M Daniele Fallin, William B Isaacs, Nilanjin Chatterjee, Robert Welch, Wen-Yi Huang, Richard B Hayes.   

Abstract

BACKGROUND: alpha-Methylacyl-CoA racemase (AMACR), an enzyme involved in oxidation of branched chain fatty acids and cholesterol metabolites, as well as ibuprofen metabolism, is overexpressed in colorectal adenomas and cancer. AMACR gene variants have been associated with hereditary prostate cancer, but no studies have evaluated their etiologic role in colorectal carcinogenesis.
METHODS: We conducted a case-control study of 725 advanced distal colorectal adenoma cases and 729 frequency-matched controls from the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Seven AMACR polymorphisms were genotyped. Unconditional logistic regression models were used to evaluate the associations adjusting for age at randomization and gender.
RESULTS: The 201L allele of S201L [TT versus CC: odds ratio (OR), 1.74; 95% confidence interval (95% CI), 1.15-2.62; TC versus CC: OR, 1.17; 95% CI, 0.93-1.49] and the 277E allele of K277E (GG versus AA: OR, 1.66; 95% CI, 1.03-2.68; GA versus AA: OR, 1.21; 95% CI, 0.96-1.53) were associated with increased risk of advanced distal colorectal adenoma (both P(trend) </= 0.02); the TGTGCG haplotype of six informative single nucleotide polymorphisms was also associated with increased risk (OR, 1.27; 95% CI, 1.03-1.55). Regular ibuprofen users who were homozygous for the variant allele at either M9V or D175G were at reduced risk for adenoma (both P(interaction) < 0.05).
CONCLUSION: Our study identified variants in AMACR associated with advanced distal colorectal adenoma and pointed to potential interactions with ibuprofen use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684125     DOI: 10.1158/1055-9965.EPI-07-0117

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Non-synonymous variants in the AMACR gene are associated with schizophrenia.

Authors:  Irina N Bespalova; Martina Durner; Benjamin P Ritter; Gary W Angelo; Enrique Rossy-Fullana; Jose Carrion-Baralt; James Schmeidler; Jeremy M Silverman
Journal:  Schizophr Res       Date:  2010-09-26       Impact factor: 4.939

2.  Alpha-methylacyl-CoA racemase expression is upregulated in gastric adenocarcinoma: a study of 249 cases.

Authors:  Camtu D Truong; Wei Li; Wei Feng; Philip Cagle; Thaer Khoury; Sadir Alrawi; Keping Xie; James Yao; Dongfeng Tan
Journal:  Int J Clin Exp Pathol       Date:  2008-04-10

3.  Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.

Authors:  Sven Gunia; Matthias May; Katharina Scholmann; Stephan Störkel; Bernd Hoschke; Stefan Koch; Manfred Dietel; Glen Kristiansen
Journal:  Virchows Arch       Date:  2008-07-22       Impact factor: 4.064

4.  AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.

Authors:  Ying-En Lee; Hong-Lin He; Sung-Wei Lee; Tzu-Ju Chen; Kwang-Yu Chang; Chung-Hsi Hsing; Chien-Feng Li
Journal:  Tumour Biol       Date:  2014-05-16

5.  Alpha-methylacyl-coenzyme a racemase-expressing urachal adenocarcinoma of the abdominal wall.

Authors:  Yun-Sok Ha; Young-Won Kim; Byung-Dal Min; Ok-Jun Lee; Yong-June Kim; Seok-Joong Yun; Sang-Cheol Lee; Wun-Jae Kim
Journal:  Korean J Urol       Date:  2010-07-20

6.  B-cell lymphoma 2 is associated with advanced tumor grade and clinical stage, and reduced overall survival in young Chinese patients with colorectal carcinoma.

Authors:  Jiasheng Wang; Gan He; Qiang Yang; Lian Bai; Bin Jian; Qugang Li; Zhongfu Li
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

7.  Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.

Authors:  Xiang Zhang; Irwin Leav; Monica P Revelo; Ranjan Deka; Mario Medvedovic; Zhong Jiang; Shuk-Mei Ho
Journal:  PLoS Genet       Date:  2009-01-16       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.